Grace R. Tarabay

Grace Tarabay practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Grace Tarabay's NPI, 1235103847, was assigned on February 13, 2006. Grace Tarabay holds Pennsylvania license MD423739.

Grace Tarabay's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Grace Tarabay's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Grace Tarabay is also affiliated with UPMC Passavant-McCandless. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Grace Tarabay to 3 more hospitals, 1 group practice or clinic, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Grace Tarabay practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Grace Tarabay's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Grace Tarabay is licensed in Pennsylvania.

CMS data shows 1,465 Medicare services from Grace Tarabay across 6 procedure codes in 2024, for 376 Medicare patients. Medicare paid $98,717 for them.

CMS counts 376 Medicare patients who saw Grace Tarabay in 2024. The largest group is 65 to 74, with 191 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Grace Tarabay's median patient age at 72, with 73% women.

In 2024, Grace Tarabay wrote 3,056 Medicare Part D claims for 516 patients. 80% of them were for generic drugs. CMS names the drug for 2,740 of them, across 52 drugs with 11 or more claims each, at $3,032,145 in total drug cost. In 2023, CMS named 1,665 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Grace Tarabay for performance year 2024, reported as part of a group. Grace Tarabay accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Grace Tarabay to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 6 general payments to Grace Tarabay from 3 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 79% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,089.